The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations
Open accessAbstract
Vaccines constitute the most effective medications in public health as they control and prevent the spread of infectious diseases and reduce mortality. Similar to other medications, allergic reactions can occur during vaccination. While most reactions are neither frequent nor serious, anaphylactic reactions are potentially life-threatening allergic reactions that are encountered rarely, but can cause serious complications. The allergic responses caused by vaccines can stem from activation of mast cells via Fcε receptor-1 type I reaction, mediated by the interaction between immunoglobulin E (IgE) antibodies against a particular vaccine, and occur within minutes or up to four hours. The type IV allergic reactions initiate 48 h after vaccination and demonstrate their peak between 72 and 96 h. Non-IgE-mediated mast cell degranulation via activation of the complement system and via activation of the Mas-related G protein-coupled receptor X2 can also induce allergic reactions. Reactions are more often caused by inert substances, called excipients, which are added to vaccines to improve stability and absorption, increase solubility, influence palatability, or create a distinctive appearance, and not by the active vaccine itself. Polyethylene glycol, also known as macrogol, in the currently available Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines, and polysorbate 80, also known as Tween 80, in AstraZeneca and Johnson & Johnson COVID-19 vaccines, are excipients mostly incriminated for allergic reactions. This review will summarize the current state of knowledge of immediate and delayed allergic reactions in the currently available vaccines against COVID-19, together with the general and specific therapeutic considerations. These considerations include: The incidence of allergic reactions and deaths under investigation with the available vaccines, application of vaccination in patients with mast cell disease, patients who developed an allergy during the first dose, vasovagal symptoms masquerading as allergic reactions, the COVID-19 vaccination in pregnancy, deaths associated with COVID-19 vaccination, and questions arising in managing of this current ordeal. Careful vaccine-safety surveillance over time, in conjunction with the elucidation of mechanisms of adverse events across different COVID-19 vaccine platforms, will contribute to the development of a safe vaccine strategy. Allergists’ expertise in proper diagnosis and treatment of allergic reactions is vital for the screening of high-risk individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“Both vaccines use a lipid nanoparticle (LNP) carrier system to prevent rapid enzymatic degradation of mRNA and facilitate in vivo delivery [19].”
BackgroundSARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · cited 1×
“The virus in which the DNA is inserted may lose its ability to replicate [26,29].”
BackgroundMaintaining safety with SARS-CoV-2 vaccines
Castells, M. C., & Phillips, E. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2035343 · Cited by 395 · cited 1×
“Vaccinated subjects with very high IgE concentrations thereby respond poorly to the vaccine [69].”
BackgroundRisk of anaphylaxis after vaccination in children and adults.
McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.048 · Cited by 381
Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines
Moghimi, S. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.030 · Cited by 150
Cited by
Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C. A. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01630-0 · Cited by 637
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01556-7 · Cited by 394
Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., Zaccardi, F., Watkinson, P., Shankar-Hari, M., Doidge, J., et al. (2021) · BMJ · doi:10.1136/bmj.n1931 · Cited by 371
Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M. H., Turner, D. L., & Turner, R. J. (2021) · Vaccines · doi:10.3390/vaccines9050467 · Cited by 339
Side effects and perceptions following Sinopharm COVID-19 vaccination
Saeed, B. Q., Al-Shahrabi, R., Alhaj, S. S., Alkokhardi, Z. M., & Adrees, A. O. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.08.013 · Cited by 278
Metadata
- Authors
- Kounis, N. G., Koniari, I., de Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S. F., Gogos, C., Kouni, S. N., Kounis, G. N., Calogiuri, G., & Hung, M.-Y.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-03-05
- Volume
- 9
- Issue
- 3
- Pages
- 221
- ISSN
- 2076-393X (ISSN-L)
- OpenAlex
- W3135054238
- Cited by
- 192
- References
- 6
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. https://app.cochat.ai/papers/10.3390/vaccines9030221
- The paper
- Kounis, N. G., Koniari, I., de Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S. F., Gogos, C., Kouni, S. N., Kounis, G. N., Calogiuri, G., & Hung, M.-Y. (2021). Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines. https://doi.org/10.3390/vaccines9030221
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.